Sagimet Biosciences (SGMT) Competitors $3.84 -0.09 (-2.29%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT vs. ERAS, SANA, ZVRA, ALT, SNDL, ORKA, KMDA, RVNC, TECX, and TSHAShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Erasca (ERAS), Sana Biotechnology (SANA), Zevra Therapeutics (ZVRA), Altimmune (ALT), SNDL (SNDL), Oruka Therapeutics (ORKA), Kamada (KMDA), Revance Therapeutics (RVNC), Tectonic Therapeutic (TECX), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Erasca Sana Biotechnology Zevra Therapeutics Altimmune SNDL Oruka Therapeutics Kamada Revance Therapeutics Tectonic Therapeutic Taysha Gene Therapies Sagimet Biosciences (NASDAQ:SGMT) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk. Does the media favor SGMT or ERAS? In the previous week, Erasca had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 11 mentions for Erasca and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.12 beat Erasca's score of 0.75 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, SGMT or ERAS? Sagimet Biosciences has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Is SGMT or ERAS more profitable? Sagimet Biosciences' return on equity of -23.63% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% Erasca N/A -42.26%-34.97% Does the MarketBeat Community believe in SGMT or ERAS? Erasca received 3 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.43% of users gave Sagimet Biosciences an outperform vote while only 75.00% of users gave Erasca an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2796.43% Underperform Votes13.57%ErascaOutperform Votes3075.00% Underperform Votes1025.00% Do analysts recommend SGMT or ERAS? Sagimet Biosciences currently has a consensus price target of $22.40, indicating a potential upside of 469.97%. Erasca has a consensus price target of $4.83, indicating a potential upside of 224.38%. Given Sagimet Biosciences' higher possible upside, equities analysts clearly believe Sagimet Biosciences is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Erasca 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in SGMT or ERAS? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 17.6% of Sagimet Biosciences shares are held by insiders. Comparatively, 21.5% of Erasca shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, SGMT or ERAS? Sagimet Biosciences has higher revenue and earnings than Erasca. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M60.28-$27.88M-$1.43-2.75ErascaN/AN/A-$125.04M-$0.74-2.01 SummarySagimet Biosciences beats Erasca on 9 of the 16 factors compared between the two stocks. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.55M$6.85B$5.54B$7.93BDividend YieldN/A2.96%5.09%4.23%P/E Ratio-2.757.3222.5718.54Price / Sales60.28241.43399.89103.29Price / CashN/A65.8538.1834.62Price / Book0.996.486.774.25Net Income-$27.88M$143.41M$3.22B$248.18M7 Day Performance24.76%1.91%1.07%0.91%1 Month Performance55.95%4.28%2.46%2.58%1 Year Performance-11.69%-3.87%15.74%4.02% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences2.6799 of 5 stars$3.84-2.3%$22.40+483.3%-4.4%$117.49M$2M-2.688Positive NewsERASErasca2.9521 of 5 stars$1.40+0.7%$4.83+245.2%-28.7%$396.57MN/A-1.69120Analyst ForecastNews CoverageSANASana Biotechnology1.9143 of 5 stars$1.76-0.6%$10.80+513.6%-80.3%$396.04MN/A-1.26380Upcoming EarningsZVRAZevra Therapeutics2.7649 of 5 stars$7.20flat$22.29+209.5%+66.1%$393.69M$23.61M-3.6520Upcoming EarningsNews CoveragePositive NewsALTAltimmune2.348 of 5 stars$5.06-0.2%$20.83+311.7%-26.9%$389.69M$20,000.00-3.2650Upcoming EarningsNews CoverageSNDLSNDL3.0046 of 5 stars$1.47-1.3%$3.63+146.6%-36.5%$386.28M$920.45M-4.74580Earnings ReportNews CoverageORKAOruka Therapeutics3.1598 of 5 stars$10.28+1.9%$39.86+287.7%N/A$384.89MN/A-1.64N/AUpcoming EarningsAnalyst RevisionNews CoverageKMDAKamada3.9859 of 5 stars$6.64-0.7%$14.67+120.9%+22.3%$381.67M$160.95M23.71360Upcoming EarningsShort Interest ↓RVNCRevance Therapeutics2.484 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Upcoming EarningsTECXTectonic Therapeutic2.595 of 5 stars$20.18-4.3%$72.40+258.8%N/A$376.62MN/A-3.43120Upcoming EarningsShort Interest ↑News CoverageTSHATaysha Gene Therapies1.9764 of 5 stars$1.80+2.3%$6.63+268.1%-0.4%$369.10M$8.33M2.86180News CoverageGap Up Related Companies and Tools Related Companies Erasca Competitors Sana Biotechnology Competitors Zevra Therapeutics Competitors Altimmune Competitors SNDL Competitors Oruka Therapeutics Competitors Kamada Competitors Revance Therapeutics Competitors Tectonic Therapeutic Competitors Taysha Gene Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMT) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SGMT Stock Free SGMT Stock Alerts